This activity is supported by an educational grant from Eisai, Inc.
Chemotherapy-Induced Nausea and Vomiting: Emerging Therapies and New Guidelines
Diagnosing and Treating Chemotherapy-Induced Nausea and Vomiting: Understanding the Need and Clinical Data for Best Patient Care
Hope S. Rugo, MD
Professor of Medicine
Director, Breast Oncology Clinical Trials Education
Department of Medicine, Division of Hematology/Oncology
University of California San Francisco Medical Center
San Francisco, California
Current Clinical Practice for Chemotherapy-Induced Nausea and Vomiting: Understanding the Up-to-Date Evidence-Based Guidelines for Prevention and Treatment
Una Hopkins, RN, DNP
Assistant Professor, New York University Nursing
Administrative Director, White Plains Hospital Cancer Center
White Plains, New York
Contributing Editorial Support
New York, New York
Beatriz Manzor Mitrzyk, PharmD, BCPS
This activity is designed to educate oncologists and oncology nurses on the optimal management of chemotherapy-induced nausea and vomiting (CINV), education on the efficacy and safety data for current and emerging agents for the treatment of CINV, and current guidelines for management of CINV.
Upon completion of this educational activity, participants should be able to:
Target Audience: Oncologists and oncology nurses
Type of Activity: Knowledge
Release date: March 19,2014
Expiration date: March 19, 2015
Estimated time to complete activity: 2 hours
Identify patients at risk for developing CINV who would benefit from early intervention
Demonstrate knowledge of the current guidelines for CINV
Develop an evidence-based treatment regimen for a patient at risk for developing CINV
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Cincinnati and ArcMesa Educators, LLC. The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.
The University of Cincinnati designates this Enduring Material Activity for a maximum of 2 AMA PRA Category 1 Credit
™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants must read the article, complete the posttest achieving a passing score of 70% or higher, and complete an evaluation and request for credit.
According to the disclosure policy of the University of Cincinnati, all persons who are in a position to control content are required to disclose any relevant financial relationships with commercial interests. If a conflict is identified, it is the responsibility of the University of Cincinnati to initiate a mechanism to resolve the conflict(s) The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. All educational materials are reviewed for fair balance, scientific objectivity of studies reported and levels of evidence.
Hope Rugo, MD, has disclosed the following relevant commercial financial relationships.
Speaker's Bureau - Genomic Health
Una Hopkins, RN, DNP, has disclosed the following relevant commercial financial relationships:
Advisory Board - Eisai
Speaker's Bureau - Eisai
Anna Azyolinsky, PhD, DNP, has disclosed the following relevant commercial financial relationships:
Shareholder - BMY, PFE, AGN
Beatriz Manzor Mitrzyk, PharmD, BCPS, has no relevant financial relationships with commercial interests to disclose.
The staff of ArcMesa Educators, LLC has no relevant financial relationships with commercial interests to disclose.
University of Cincinnati
Planning Staff—Susan P. Tyler, MEd, CMP, CCMEP, has no relevant financial relationships with commercial interests to disclose.
CME Physician Reviewer - Rick Ricer, MD, has no relevant financial relationships with commercial interests to disclose.
Required: Windows® 7, Vista, XP, 2003 Server or 2000
Required: Mac OS® X 10.4.11 (Tiger®) or newer
Off-Label Disclosure and Disclaimer
The contents of this CME online activity may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside crrent approved labeling is considered experimental and are advised to consult prescribing information for these products.
For additional information about approved uses, including approved indications, contraindictions, and warnings, participants are advised to consult prescribing information for all products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient's medical condition.
The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of The University of Cincinnati, the Pharmacy Times Office of Continuing Professional Education, or any of the companies that provided commercial support for this CME activity.
Click here to read the supplement